Abemaciclib and Pembrolizumab in Metastatic or Recurrent Head and Neck Cancer
Status:
Terminated
Trial end date:
2020-04-03
Target enrollment:
Participant gender:
Summary
To assess the objective response rate of tumor lesions to abemaciclib in combination with
pembrolizumab in patients with metastatic or recurrent squamous cell carcinoma of head and
neck.